Modern treatment of malignant lymphomas: a multidisciplinary approach? The Kaplan Memorial Lecture.
The aim of this review is to examine critically, in Hodgkin's disease and in non-Hodgkin's lymphomas, (a) whether combined modality treatment is superior to optimal radiotherapy or chemotherapy alone in most stages of the disease; (b) whether its indications could be further expanded by the use of new drug regimens and newer radiation techniques that can now substantially reduce the risk of long-term iatrogenic morbidity; and (c) whether it may become a necessary approach in the future because staging laparotomy and even lymphangiography are progressively falling into disuse. In conclusion, for the next decade or so, I do not foresee a departure from complex treatment programs. Although fewer patients are being referred to major research centers, the treatment of malignant lymphomas is not ready as yet to be relegated to the care of the single physician in a private office or local hospital.
Bonadonna
G
G
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005544:Forecasting; D006801:Humans; D007938:Leukemia / Q000139:chemically induced / Q000453:epidemiology; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000453:epidemiology; D011379:Prognosis; D012074:Remission Induction; D012306:Risk; D016896:Treatment Outcome